hrp0086p1-p814 | Syndromes: Mechanisms and Management P1 | ESPE2016

Changes to Thyroid Function (TF) Following Treatment with Growth Hormone (GH) Therapy in Children with Prader-Willi Syndrome (PWS)

Musthaffa Yassmin , Scheermeyer Elly , Hughes Ian , Harris Mark , Crock Patricia , Leong Gary

Background: Normal TF is necessary for optimal growth. Changes in the hypothalamic-pituitary-thyroid (HPT) axis following GH therapy are reported. GH therapy has been suggested to centrally inhibit TSH production as well as peripherally increasing T4 to T3 conversion which increases negative feedback on TSH production. Hypothalamic dysfunction is a feature of PWS, therefore these patients may be at risk of developing central hypothyroidism associated with GH therapy.<p cla...

hrp0094p1-75 | Fetal Endocrinology and Multisystem Disorders A | ESPE2021

Congenital hyperinsulinism diagnosed after 12 months can have a monogenic aetiology

Hopkins Jasmin , Childs Alexandra , Hewat Thomas , Patel Kashyap , Houghton Jayne , Johnson Matthew , Laver Thomas , Flanagan Sarah ,

Background: Congenital hyperinsulinism (HI) is characterised by inappropriate insulin secretion despite low blood glucose which is commonly diagnosed in infancy (before the age of 12 months). Screening of the >20 known genes identifies a mutation in over 45% of cases. The likelihood of identifying a mutation in a known gene in individuals diagnosed after 12 months is not currently known.Aim: We aimed to identify the ...

hrp0094p1-126 | Growth A | ESPE2021

Identification and tissue-specific characterization of novel SHOX-regulated genes in zebrafish highlights SOX family members among other genes

Hoffmann Sandra , Roeth Ralph , Diebold Sabrina , Gogel Jasmin , Hassel David , Just Steffen , Rappold Gudrun A ,

SHOX deficiency causes a spectrum of clinical phenotypes related to skeletal dysplasia and short stature, including Léri-Weill dyschondrosteosis, Langer mesomelic dysplasia, Turner syndrome, and idiopathic short stature. SHOX controls chondrocyte proliferation and differentiation, bone maturation, cellular growth arrest and apoptosis via transcriptional regulation of its direct target genes NPPB, FGFR3, and CTGF. However, our u...

hrp0086p2-p292 | Diabetes P2 | ESPE2016

Use of Continuous Glucose Monitoring Helps Selecting Insulin Therapy in Thalassemic Adolescents with Glycemic abnormalities

Soliman Ashraf , Alyafie Fawzia , Yassin Mohamed , Aldarsy Nagwa

Background: Continuous Glucose Monitoring (CGMS) is a useful method to detect the variability of glucose fluctuations and offers the opportunity for better assessment of glucose homeostasis in TM patients and response to therapy.Objective and hypotheses: Does real-life monitoring of blood glucose add to the therapeutic approach to patients with TM who have glycemic abnormalities?Method: In two thalassemic adolescents with glycemic ...

hrp0097p1-132 | Growth and Syndromes | ESPE2023

One-year growth response and cost-effectiveness to Human recombinant growth hormone in girls with Turner Syndrome: Results from a large Egyptian retrospective study

Ibrahim Amany , Atef Abeer , Badawi Nora , Yassin Sahar , Helmy Eatemad

FDA licensed the use of human recombinant growth hormone (hGH) in girls with Turner Syndrome (TS) in 1997 as short stature is a consistent feature of this syndrome.Objective: we aimed to assess our 1-year experience of treating short girls with TS, to calculate their growth velocity, to analyze the patients’ characteristics and to investigate the possible factors that might affect their height gain.Me...

hrp0097p2-86 | Multisystem Endocrine Disorders | ESPE2023

Consequences of Hypogonadism and Potential Benefits of Sex Steroid therapy (HRT) in Children and Adolescents with Beta Thalassemia Major (BTM).

Soliman Ashraf , Yassin Mohamed , Alyafei Fawzia , Alaaraj Nada , Soliman Nada

Introduction: A recent review from 14 Mediterranean and Middle East countries (n=4477, mean age = 16.5 years) showed that the pooled prevalence of delayed puberty / hypogonadism in patients with BTM was 45.6%.Objectives: We reviewed the literature (Pubmed, Google scholar, Scopus, Research gate) (1995: 2022) on the consequences of hypogonadism and benefits of Sex Steroid therapy (HRT) in children and adolescents ...

hrp0089p3-p253 | Growth &amp; Syndromes P3 | ESPE2018

Tall Stature: A Diagnosis is Sometimes Difficult

Kherra Sakina , Bekakcha Hadjira , Boutaba Mounia , Talbi Fatiha , Behidj Yasmina , Zeroual Zoulikha

Background: Tall stature is defined as height >02 S.D. above the population mean. The most common cause is normal familial tall stature, but some cases are pathological and require special attention.Observations: We report four clinical cases corresponding to four diagnostic categories. We describe the diagnostic approach and difficulties encountered through these cases.Case 1: A boy aged 25 months was referred f...

hrp0097p1-593 | Thyroid | ESPE2023

Congenital malformations in permanent and transient congenital hypothyroidism – prevalence and etiology

Ouarezki Yasmina , Shepherd Sheila , Jones Jeremy , Abubaker Alghanay A , Smith Sarah , Shaikh Guftar , Donaldson Malcolm

Background: An increased prevalence of extra-thyroidal congenital malformations in infants with congenital hypothyroidism (CH) is well established. However, accurate estimation of prevalence figures requires careful distinction between permanent and transient CH. Moreover, the mechanisms resulting in congenital malformations are not well understood.Study aim: To estimate the prevalence of cardiac, extra-cardiac and/or sy...

hrp0095p2-245 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

To give or not to give GnRH agonists in central precocious puberty due to pituitary microadenoma?

Abdelmeguid Yasmine , Elsayed Shaymaa , Raafat Shaymaa

Background: Functioning gonadotroph adenomas (FGAs) are very rare gonadotropin-secreting pituitary adenomas. Clinically, FGAs present only with mass effects. Nevertheless, central precocious puberty (CPP) has also been reported. Published data have demonstrated controversial opinions on the use of GnRH agonists in these patients, considering the risk of increase in tumor size and stimulating gonadotropin secretion. We herein report 3 cases diagnosed with CPP d...

hrp0094p2-384 | Pituitary, neuroendocrinology and puberty | ESPE2021

Basal LH as a screening test for diagnosis of central precocious puberty

Raafat Shaymaa , Abdelmeguid Yasmine , Fawzy Dina ,

Introduction: Central precocious puberty (CPP) refers to the development of secondary sex characteristics before ages 8 and 9 years in girls and boys, respectively. It is either due to organic brain lesion or idiopathic. Conventionally, Gonadotropin Releasing Hormone (GnRH) stimulation test is a mainstay tool for diagnosis of central precocious puberty in pediatrics. However, it is time consuming and expensive. Therefore, this study was aiming to find an alter...